Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Financing Activities (2020 - 2024)

Historic Cash from Financing Activities for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to $143.1 million.

  • Therapeutics' Cash from Financing Activities rose 3114781.66% to $143.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $152.9 million, marking a year-over-year increase of 1046337.25%. This contributed to the annual value of $152.9 million for FY2024, which is 1046337.25% up from last year.
  • Latest data reveals that Therapeutics reported Cash from Financing Activities of $143.1 million as of Q4 2024, which was up 3114781.66% from $701000.0 recorded in Q2 2024.
  • Therapeutics' 5-year Cash from Financing Activities high stood at $143.1 million for Q4 2024, and its period low was $106000.0 during Q3 2023.
  • Over the past 5 years, Therapeutics' median Cash from Financing Activities value was $864000.0 (recorded in 2020), while the average stood at $26.4 million.
  • Per our database at Business Quant, Therapeutics' Cash from Financing Activities crashed by 9939.22% in 2023 and then surged by 3114781.66% in 2024.
  • Therapeutics' Cash from Financing Activities (Quarter) stood at $4.6 million in 2020, then crashed by 86.82% to $601000.0 in 2021, then soared by 12438.94% to $75.4 million in 2022, then tumbled by 99.39% to $458000.0 in 2023, then soared by 31147.82% to $143.1 million in 2024.
  • Its Cash from Financing Activities was $143.1 million in Q4 2024, compared to $701000.0 in Q2 2024 and $9.0 million in Q1 2024.